• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » The Antipsychotics Weigh In [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

The Antipsychotics Weigh In [60 Sec Psych]

September 23, 2020

When it comes to weight gain on antipsychotics, most of what we know is from industry sponsored trials, and most of them were done on Caucasian patients. Few of those studies compare the antipsychotics side by side, which leaves us guessing as to how they compare across side effects. This study changes that. [Link]


Published On: 9/23/2020


Duration: 2 minutes, 19 seconds


Transcript:


When it comes to weight gain on antipsychotics, most of what we know is from industry sponsored trials, and most of them were done on Caucasian patients. Few of those studies compare the antipsychotics side by side, which leaves us guessing as to how they compare across side effects.

This study changes that. It’s a huge random controlled trial of over two thousand patients with schizophrenia  in China.They were randomized, get this – to 7 different antipsychotics. I don’t think I’ve ever seen a 7-arm trial. The catie only had 5.

Their focus was on metabolic outcomes – and I’m going to skip right to the bottom line.

Here’s how the 7 stacked up in terms of risk for metabolic syndrome; Weight Gain, Waist Circumference, Blood Pressure, Glucose and Triglycerides – the worst offender was Olanzapine.

Then Quetiapine, 3rd was perphenazine, 4. risperidone. Tied for 5th and 6th place were Aripiprazole and haloperidol.  Ziprasidone/Geodon came in with the lowest risk.

To give you an idea of the spread there, olanzapine, quetiapine and perphenazine were about 3 times more likely than ziprasidone to cause metabolic syndrome while the other 3 were twice as likely.

The authors concluded that the ranking of antipsychotics by metabolic effects was similar for the Chinese as we see in other studies of Caucasians.

They also found you could detect these changes in as early as 2 weeks with weight and waist circumference. 

Perhaps the most novel finding here is that the typicals are almost as bad as atypicals when it comes to metabolic syndrome.

Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_cover_sm.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • shutterstock_495683782.jpg
    General Psychiatry

    The Other Freud 1

    Sigmund Freud’s theories are challenged by his granddaughter, Sophie Freud.



    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.